X4 Pharmaceuticals Inc (XFOR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $318.59M
Last updated: Nov 17, 2026 at 11:05 AM ET
X4 Pharmaceuticals Inc (XFOR) Earnings: Report Dates and Results
X4 Pharmaceuticals (XFOR) is expected to report earnings on Mar 15, 2027. In the quarter ended Sep 30, 2026, X4 Pharmaceuticals reported EPS of -$0.16, above the -$0.19 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
XFOR has an expected report date of Mar 15, 2027.
XFOR Earnings Call
The latest XFOR earnings call transcript on file is labeled 2025Q1.
Read the 2025Q1 transcriptEarnings History
Of the 36 quarters below that had an estimate, XFOR beat 17 and missed 19. Revenue for the quarter ended Sep 30, 2026 was $2.88M, up 63.6% from $1.76M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.16 | -$0.19 | -$0.22 - -$0.16 | +15.79% | Beat | N/A | 5 | 1 up, 0 down | Nov 4, 2026 | $2.88M |
| Jun 30, 2026 | -$0.13 | -$0.19 | -$0.22 - -$0.14 | +31.58% | Beat | N/A | 5 | N/A | Aug 6, 2026 | $8.81M |
| Mar 31, 2026 | -$0.16 | -$0.20 | -$0.21 - -$0.19 | +20.00% | Beat | -500.0% | 3 | N/A | May 6, 2026 | $2.71M |
| Dec 31, 2025 | -$0.22 | -$0.35 | -$0.56 - -$0.24 | +36.69% | Beat | N/A | 4 | 2 up, 0 down | Mar 17, 2026 | $2.14M |
| Sep 30, 2025 | -$0.69 | -$0.79 | -$1.42 - -$0.42 | +12.66% | Beat | N/A | 3 | 0 up, 1 down | Nov 5, 2025 | $1.76M |
| Jun 30, 2025 | -$3.47 | -$4.34 | -$5.57 - -$3.57 | +20.05% | Beat | N/A | 3 | 0 up, 1 down | Aug 8, 2025 | $1.97M |
| Mar 31, 2025 | $0.04 | -$3.75 | -$5.70 - -$0.60 | +101.07% | Beat | N/A | 4 | 1 up, 1 down | May 1, 2025 | $28.81M |
| Dec 31, 2024 | -$0.20 | -$0.16 | -$0.17 - -$0.13 | -26.98% | Miss | N/A | 4 | 1 up, 0 down | Mar 25, 2025 | $1.43M |
| Sep 30, 2024 | -$5.40 | -$5.16 | -$5.71 - -$4.50 | -4.65% | Miss | N/A | 7 | 0 up, 0 down | Nov 13, 2024 | $560000 |
| Jun 30, 2024 | -$2.12 | $0.75 | -$7.21 - $10.21 | -382.67% | Miss | N/A | 7 | 0 up, 0 down | Aug 8, 2024 | $563000 |
| Mar 31, 2024 | -$0.26 | -$0.16 | -$0.22 - -$0.14 | -62.50% | Miss | N/A | 7 | 0 up, 1 down | May 7, 2024 | N/A |
| Dec 31, 2023 | -$3.00 | -$4.55 | -$5.11 - -$4.20 | +34.07% | Beat | N/A | 7 | 0 up, 0 down | Mar 21, 2024 | $3.06M |
| Sep 30, 2023 | -$0.30 | -$4.29 | -$5.71 - -$3.90 | +93.01% | Beat | N/A | 9 | 0 up, 0 down | Nov 9, 2023 | N/A |
| Jun 30, 2023 | -$9.90 | -$4.93 | -$6.61 - -$3.60 | -100.81% | Miss | N/A | 9 | 0 up, 0 down | Aug 10, 2023 | N/A |
| Mar 31, 2023 | -$0.16 | -$0.22 | -$0.27 - -$0.17 | +27.27% | Beat | N/A | 7 | 0 up, 0 down | May 4, 2023 | N/A |
| Dec 31, 2022 | -$8.70 | -$7.24 | -$10.81 - -$5.41 | -20.17% | Miss | N/A | 8 | 1 up, 0 down | Mar 21, 2023 | N/A |
| Sep 30, 2022 | -$7.80 | -$9.53 | -$13.81 - -$6.91 | +18.15% | Beat | N/A | 5 | 0 up, 0 down | Nov 3, 2022 | N/A |
| Jun 30, 2022 | -$18.00 | -$19.25 | -$21.32 - -$17.42 | +6.49% | Beat | N/A | 7 | 0 up, 1 down | Aug 4, 2022 | N/A |
| Mar 31, 2022 | -$21.60 | -$18.53 | -$20.42 - -$15.02 | -16.57% | Miss | N/A | 7 | 0 up, 0 down | May 12, 2022 | $176000 |
| Dec 31, 2021 | -$0.90 | -$0.68 | -$0.82 - -$0.47 | -32.35% | Miss | N/A | 7 | N/A | Mar 17, 2022 | N/A |
| Sep 30, 2021 | -$22.80 | -$21.30 | -$24.62 - -$15.92 | -7.04% | Miss | N/A | 8 | N/A | Nov 4, 2021 | N/A |
| Jun 30, 2021 | -$22.20 | -$22.08 | -$26.43 - -$19.52 | -0.54% | Miss | N/A | 8 | N/A | Aug 3, 2021 | $57000 |
| Mar 31, 2021 | -$39.00 | -$25.76 | -$28.53 - -$16.82 | -51.40% | Miss | N/A | 7 | N/A | May 6, 2021 | N/A |
| Dec 31, 2020 | -$0.91 | -$0.90 | -$1.10 - -$0.74 | -1.11% | Miss | N/A | 9 | N/A | Mar 4, 2021 | N/A |
| Sep 30, 2020 | -$26.10 | -$21.97 | -$24.02 - -$19.52 | -18.80% | Miss | N/A | 8 | N/A | Nov 5, 2020 | N/A |
| Jun 30, 2020 | -$22.80 | -$21.54 | -$23.12 - -$19.22 | -5.85% | Miss | N/A | 8 | N/A | Jul 30, 2020 | N/A |
| Mar 31, 2020 | -$0.56 | -$0.80 | -$0.88 - -$0.71 | +30.00% | Beat | N/A | 8 | N/A | May 7, 2020 | $3.00M |
| Dec 31, 2019 | -$19.80 | -$25.65 | -$33.63 - -$20.42 | +22.81% | Beat | N/A | 8 | N/A | Mar 12, 2020 | N/A |
| Sep 30, 2019 | -$36.60 | -$32.00 | -$34.53 - -$28.53 | -14.38% | Miss | N/A | 4 | N/A | Nov 7, 2019 | N/A |
| Jun 30, 2019 | -$30.60 | -$29.10 | -$36.34 - -$25.23 | -5.15% | Miss | N/A | 4 | N/A | Aug 6, 2019 | N/A |
| Mar 31, 2019 | -$200.10 | -$98.97 | N/A | -102.18% | Miss | N/A | N/A | N/A | May 15, 2019 | $3.50M |
| Dec 31, 2018 | -$3.92 | -$4.44 | N/A | +11.71% | Beat | N/A | N/A | N/A | Mar 11, 2019 | N/A |
| Sep 30, 2018 | -$4.56 | -$3.88 | N/A | -17.53% | Miss | N/A | N/A | N/A | Nov 9, 2018 | N/A |
| Jun 30, 2018 | -$5.10 | -$4.90 | N/A | -4.08% | Miss | N/A | N/A | N/A | Aug 13, 2018 | N/A |
| Mar 31, 2018 | -$4.44 | -$6.24 | N/A | +28.85% | Beat | N/A | N/A | N/A | May 10, 2018 | N/A |
| Dec 31, 2017 | -$10.08 | -$17.80 | N/A | +43.37% | Beat | N/A | N/A | N/A | Mar 9, 2018 | N/A |
| Sep 30, 2017 | -$24.36 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 17, 2017 | N/A |
| Jun 30, 2017 | -$0.53 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 20, 2017 | N/A |
| Mar 31, 2017 | -$0.50 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 4, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$4.34, after -$7.98 the year before. It was -$35.47 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$4.34 | N/A |
| Dec 31, 2024 | -$7.98 | N/A |
| Dec 31, 2023 | -$13.36 | N/A |
| Dec 31, 2022 | -$56.10 | N/A |
| Dec 31, 2021 | -$84.90 | N/A |
| Dec 31, 2020 | -$50.37 | N/A |
| Dec 31, 2019 | -$287.10 | N/A |
| Dec 31, 2018 | -$18.02 | N/A |
| Dec 31, 2017 | -$35.47 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2025Q1 for the period ended Mar 31, 2025, runs about 3,300 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q1 | Mar 31, 2025 | 3,273 | 9 | |
| 2024Q3 | Sep 30, 2024 | 5,191 | 10 |
2025Q1 Earnings Call
Opening remarks
Dan Ferry Host Thank you, operator, and good morning everyone. Presenting on today's call will be X4's Chief Executive Officer, Dr. Paula Ragan; and Chief Financial Officer, Adam Mostafa. Following prepared remarks by each, we will open the call to your questions, and will be joined by Chief Commercial Officer, Mark Baldry; and Chief Medical Officer, Dr. Christophe Arbet-Engels. As a reminder on today's call, the company will be making forward-looking statements regarding regulatory and product development plans. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in X4's most recent filings with the SEC, including last year's Form 10-K and this past quarter's Form 10-Q which is expected to be filed after market close today. Please note that the X4 investor deck was updated this morning on the company website to include slides detailing some of the data analyses mentioned in this morning's press release and on this call today. I'd now like to turn the call over to X4's President and CEO, Dr. Paula Ragan. Paula?
Paula Ragan CEO Thank you, Dan, and thanks to all of you for joining us this morning. The first quarter of 2025 was an extremely productive and value-building period for X4 with clinical trial advancement in chronic neutropenia, continued progress in the commercialization of XOLREMDI for WHIM syndrome in the US and our achievement of several significant milestones towards expanding the global potential of mavorixafor for patients. Let's begin with mavorixafor for chronic neutropenia or CN. As you know, having successfully developed mavorixafor, branded XOLREMDI for patients with WHIM syndrome in the US, we are now also developing mavorixafor for the larger indication of chronic neutropenia. There are currently about 50,000 people diagnosed with some form of CN in the US based on retrospective ICD-10 code analyses. Of those currently diagnosed with primary CN, we estimate that approximately 15,000 individuals or about 30% to 40% have remaining health challenges and continue to experience low absolute neutrophil counts or ANCs and recurrent infections despite available standard of care. We define this as the high unmet need CN patient population. And it is with this population in mind that we are launching our ongoing 4WARD trial, a global pivotal Phase III clinical trial evaluating the safety and efficacy of once-daily oral mavorixafor in people with certain chronic neutropenic conditions including primary autoimmune, idiopathic and congenital neutropenia and who are experiencing recurrent and/or serious infections. As we reported on our last call, we're now screening and enrolling participants in over 20 countries with more than 90% of our target global trial sites being activated.
Frequently Asked Questions About XFOR
When is X4 Pharmaceuticals's next earnings date?
X4 Pharmaceuticals's next earnings report is expected for Mar 15, 2027.
Did XFOR beat earnings estimates last quarter?
Yes. X4 Pharmaceuticals reported EPS of -$0.16 for the quarter ended Sep 30, 2026, above the -$0.19 estimate, a 15.79% surprise.
What EPS do analysts expect from XFOR next quarter?
The consensus EPS estimate for X4 Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.20 from 7 analysts, with estimates from -$0.27 to -$0.17.
How often does XFOR beat earnings estimates?
X4 Pharmaceuticals beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +26.36%.
XFOR pages: Overview, Earnings, Forecast, Financials, Competitors